Zoetis (ZTS) Q3 2024 Earnings Call Transcript

Zoetis reported Q3 revenue of $2.4B (+11% reported, +14% operational) and adjusted net income of $716M (+14% reported, +15% operational), and raised FY2024 guidance to $9.2–$9.3B revenue and $2.67–$2.695B adjusted net income. Key franchise metrics: Simparica $333M (+27% op), dermatology $449M (+16% op), OA pain mAbs $151M (Librela +$55M U.S., 85% U.S. clinic penetration, 1M dogs treated); Q3 mix was +8% volume / +6% price and adjusted gross margin expanded 20 bps to 70.7%. Management completed MFA divestiture (≈$400M 2023 revenue, ~30% margin) which will reduce Q4 comparables (2 months U.S., 1 month international); alternative channels now represent ~15% of U.S. business with retail up 34%.

Analysis

Zoetis’ strategic simplification (selling lower-margin livestock feed additives) plus concentrated investment in injectable biologics and DTC channels changes the growth geometry: fewer low-margin cyclic revenues and faster-recurring, higher-LTV streams. That mix shift should compress revenue seasonality and magnify operating leverage across the field force and digital spend over the next 12–24 months, but it also increases sensitivity to clinic-level adoption and supply continuity for injectables.

Alternative channels (retail, home-delivery, auto-ship) change who captures early lifetime value. As more first scripts originate outside the clinic, Zoetis gains higher volume but risks lowering per-visit ancillary revenue (diagnostics, procedures) that previously reinforced vet loyalty; over 18 months this will increase Zoetis’ bargaining power with retailers while raising the bar on margin preservation through targeted promotions.

Competitive entrants to parasiticides and dermatology will expand the category but compress pricing elasticity in any subsegment lacking clear product differentiation. Expect a two-speed response: incumbents with unique MOA or administration advantages will defend pricing; me-too entrants will spur retailer-driven promo cycles that transiently depress blended realization for the category—this is a nearer-term (quarters) threat, while meaningful share shifts require multi-year differentiation.

Key second-order risks: (1) rollout friction in injectables (supply, clinic training, reimbursement pathways) could blunt the margin rerating in the next 4–8 quarters; (2) regulatory/safety headlines for mAbs or JAK-class products would cause outsized demand shock given concentrated revenues; and (3) redistributive effects from MFA divestiture—capital redeployed to buybacks or M&A could re-accelerate EPS but reduce optionality on pipeline investment if prioritized toward financial engineering.

Key Decisions for Investors

• Long ZTS equity (12–18 month horizon): initiate on <=10% pullback from current levels, position size 3–5% portfolio. Rationale: asymmetric payoff from margin re‑mix and durable franchise cash conversion; downside risk is clinic-adoption slowdown or pricing normalization (~-15% drawdown), upside target +20–30% if adoption and margin mix continue.
• Long ZTS call spread (Jan 2026 expiry): buy 10–15% OTM calls and sell 30–40% OTM calls to finance. Max loss = premium, max gain ~3–4x premium. Use to express leveraged, capped upside on continued biologic rollouts while limiting capital at risk to a defined premium.
• Covered call (income) on ZTS (3–6 month cadence): buy shares or existing long; sell near-term 5–8% OTM calls to monetize elevated near-term sentiment and fund DTC spending risk. Expected yield enhancement ~3–6% per quarter; downside protection limited—accepts capping of upside if catalysts outperform.
• Pair trade (moderate size): long ZTS / short PAHC (Phibro) (12 months): express preference for operating leverage and scale in Zoetis vs integration risk for the MFA buyer. Size small (1–2% net exposure) given PAHC idiosyncratic integration risk; aim for 10–15% relative outperformance if Zoetis margin re‑mix converges to higher EBITDA and Phibro faces near‑term execution costs.